Afferent Pharmaceuticals, a San Mateo, CA-based developer of drugs for the treatment of a range of debilitating neurogenic disorders, completed a $55m Series C financing.
The round was led by Fidelity Management & Research Company, with participation from other crossover funds Jennison Associates LLC (on behalf of certain clients), New Leaf Ventures, Partner Fund Management, Redmile Group, Tekla Healthcare Investors and Tekla Life Science Investors, in addition to an undisclosed blue chip public investment fund.
Led by Kathleen Sereda Glaub, chief executive officer, Afferent develops novel small molecule drugs for the treatment of neurogenic respiratory, urologic and pain disorders.
The company intends to use the funds to advance its drug candidate AF-219 for the treatment of pathologic cough, including for cough in IPF patients, as well as advancement of its next candidate compound to the clinic for cardiovascular and other diseases.
FinSMEs
08/07/2015